NASDAQ:MITOStealth BioTherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.24 -0.08 (-6.06 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$1.21Now: $1.24▼$1.4450-Day Range$0.97MA: $1.74▼$3.0752-Week Range$0.90Now: $1.24▼$15.84Volume117,309 shsAverage Volume645,479 shsMarket Capitalization$43.44 millionP/E RatioN/ADividend YieldN/ABeta2.44 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in Newton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingStealth BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.20, Stealth BioTherapeutics has a potential upside of 561.3% from its current price of $1.24.Amount of Analyst CoverageStealth BioTherapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesStealth BioTherapeutics has received 65 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStealth BioTherapeutics has received 76 “underperform” votes. (Add your “underperform” vote.)Community SentimentStealth BioTherapeutics has received 53.90% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote “Outperform” if you believe MITO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStealth BioTherapeutics does not currently pay a dividend.Dividend GrowthStealth BioTherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stealth BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.66% of the stock of Stealth BioTherapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stealth BioTherapeutics are expected to decrease by -60.00% in the coming year, from ($0.15) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stealth BioTherapeutics is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stealth BioTherapeutics is -7.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.12 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MITO Previous Symbol CUSIPN/A CIKN/A Webhttp://www.stealthbt.com/ Phone617-600-6888Debt Debt-to-Equity Ratio2.19 Current Ratio1.40 Quick Ratio1.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.09 million Price / Sales2.06 Cash FlowN/A Price / Cash FlowN/A Book Value($13.84) per share Price / Book-0.09Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-96,710,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-183.59%Miscellaneous Employees57 Outstanding Shares35,030,000Market Cap$43.44 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive MITO News and Ratings via Email Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MITO Rates by TradingView Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions How has Stealth BioTherapeutics' stock been impacted by COVID-19 (Coronavirus)? Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MITO shares have decreased by 21.9% and is now trading at $1.24. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Stealth BioTherapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stealth BioTherapeutics. When is Stealth BioTherapeutics' next earnings date? Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Stealth BioTherapeutics. How were Stealth BioTherapeutics' earnings last quarter? Stealth BioTherapeutics Corp (NASDAQ:MITO) released its quarterly earnings results on Thursday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.04). View Stealth BioTherapeutics' earnings history. What price target have analysts set for MITO? 5 analysts have issued 12 month price targets for Stealth BioTherapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they expect Stealth BioTherapeutics' share price to reach $8.20 in the next twelve months. This suggests a possible upside of 561.3% from the stock's current price. View analysts' price targets for Stealth BioTherapeutics. Has Stealth BioTherapeutics been receiving favorable news coverage? Press coverage about MITO stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Stealth BioTherapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutStealth BioTherapeutics. Who are some of Stealth BioTherapeutics' key competitors? Some companies that are related to Stealth BioTherapeutics include Protagonist Therapeutics (PTGX), Abeona Therapeutics (ABEO), Recro Pharma (REPH), Selecta Biosciences (SELB), Scpharmaceuticals (SCPH), Mallinckrodt (MNK), VBI Vaccines (VBIV), Hookipa Pharma (HOOK), IVERIC bio (ISEE), Ovid Therapeutics (OVID), MEI Pharma (MEIP), Osmotica Pharmaceuticals (OSMT), Spero Therapeutics (SPRO), Endonovo Therapeutics (ENDV) and LifeVantage (LFVN). What other stocks do shareholders of Stealth BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include Tesla (TSLA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Paypal (PYPL), AbbVie (ABBV), Cronos Group (CRON), Enphase Energy (ENPH), Gilead Sciences (GILD), Ocugen (OCGN) and Okta (OKTA). Who are Stealth BioTherapeutics' key executives? Stealth BioTherapeutics' management team includes the following people: Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 54)Mr. Daniel E. Geffken, Interim Chief Financial Officer (Age 62)Mr. Mark J. Bamberger, Chief Scientific Officer (Age 66)Mr. Henry Hess, Chief Legal CounselDr. Ben R. Bronstein, Chief Medical Officer (Age 69) When did Stealth BioTherapeutics IPO? (MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager. What is Stealth BioTherapeutics' stock symbol? Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO." How do I buy shares of Stealth BioTherapeutics? Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Stealth BioTherapeutics' stock price today? One share of MITO stock can currently be purchased for approximately $1.24. How big of a company is Stealth BioTherapeutics? Stealth BioTherapeutics has a market capitalization of $43.44 million and generates $21.09 million in revenue each year. The company earns $-96,710,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Stealth BioTherapeutics employs 57 workers across the globe. View additional information about Stealth BioTherapeutics. What is Stealth BioTherapeutics' official website? The official website for Stealth BioTherapeutics is http://www.stealthbt.com/. How can I contact Stealth BioTherapeutics? Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Why does the United States have a lingering trade deficit?
